PRNewsWire
03 Sept 2026, 08:03 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
The company allegedly modified its statistical analysis plan for Deramiocel without securing the FDA's agreement before resubmitting its Biologics License Application. — Lack of FDA alignment on clinical trial analysis is a significant regulatory risk that could lead to the rejection of the drug application.
-0.80Capricor Therapeutics (CAPR) is facing a class action lawsuit alleging it made false and misleading statements regarding the clinical data analysis for its drug Deramiocel. — Securities litigation regarding core product data often leads to investor distrust and potential financial liabilities.
-0.60Which stocks this story touches
The company is named as the subject of a class action lawsuit for securities law violations.
Continue reading
6 related stories
Search tags
The company is facing a class action lawsuit for alleged securities law violations and misleading statements regarding clinical data.
The company is named as the subject of a class action lawsuit for securities law violations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
